Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA. 2021;71(3):209–49.

PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA. 2023;73(1):17–48.

PubMed  Google Scholar 

Weigelt B, Peterse JL. van ’t Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602.

Article  CAS  PubMed  Google Scholar 

Hanna WM, Slodkowska E, Lu FI, Nafisi H, Nofech-Mozes S. Comparative analysis of human epidermal growth factor receptor 2 testing in breast cancer according to 2007 and 2013 american society of clinical oncology/college of American pathologists guideline recommendations. J Clin Oncol. 2017;35(26):3039–45.

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

Article  PubMed  Google Scholar 

Vihervuori H, Korpinen K, Autere TA, Repo H, Talvinen K, Kronqvist P. Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation. Breast Cancer Res Treat. 2022;196(3):471–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Wei J, Zhang Q, Liu B: Methyltransferase-like 3 enhances cell proliferation and cisplatin resistance in natural killer/T-cell lymphoma through promoting N6-methyladenosine modification and the stability of staphylococcal nuclease and Tudor domain-containing protein 1 mRNA. Anti-Cancer Drugs 2022.

Zhao Y, Ren P, Yang Z, Wang L, Hu C: Inhibition of SND1 overcomes chemoresistance in bladder cancer cells by promoting ferroptosis. Oncol Rep 2023, 49(1).

Ha C, Hu L, Ren Y, Yang J, Xin L. SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells. Med Oncol. 2022;39(11):169.

Article  CAS  PubMed  Google Scholar 

Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, Pannell L, Fisher PB, Sarkar D. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology. 2011;53(5):1538–48.

Article  CAS  PubMed  Google Scholar 

Tsuchiya N, Nakagama H. MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutat Res. 2010;693(1–2):94–100.

Article  CAS  PubMed  Google Scholar 

Xin L, Zhao R, Lei J, Song J, Yu L, Gao R, Ha C, Ren Y, Liu X, Liu Y, et al. SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB J. 2019;33(3):3795–806.

Article  CAS  PubMed  Google Scholar 

Shen M, Wei Y, Kim H, Wan L, Jiang YZ, Hang X, Raba M, Remiszewski S, Rowicki M, Wu CG, et al. Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasis. Nat Cancer. 2022;3(1):43–59.

Article  CAS  PubMed  Google Scholar 

Shen M, Smith HA, Wei Y, Jiang YZ, Zhao S, Wang N, Rowicki M, Tang Y, Hang X, Wu S, et al. Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat Cancer. 2022;3(1):60–74.

Article  CAS  PubMed  Google Scholar 

Yu L, Di Y, Xin L, Ren Y, Liu X, Sun X, Zhang W, Yao Z, Yang J. SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis. Oncogene. 2017;36(27):3903–14.

Article  CAS  PubMed  Google Scholar 

Yu L, Xu J, Liu J, Zhang H, Sun C, Wang Q, Shi C, Zhou X, Hua D, Luo W, et al. The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients. Neuro Oncol. 2019;21(6):742–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bucker L, Lehmann U: CDH1 (E-cadherin) Gene methylation in human breast cancer: critical appraisal of a long and twisted story. Cancers 2022, 14(18).

Ratze MAK, Koorman T, Sijnesael T, Bassey-Archibong B, van de Ven R, Enserink L, Visser D, Jaksani S, Viciano I, Bakker ERM, et al. Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene. 2022;41(21):2932–44.

Article  PubMed  PubMed Central  Google Scholar 

O’Brien SJ, Fiechter C, Burton J, Hallion J, Paas M, Patel A, Rochet A, Scheurlen K, Gardner S, Eichenberger M, et al. Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021;7(1):61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Rao X, Cui Y, Zhang L, Li X, Wang B, Zheng Y, Teng L, Zhou T, Zhuo W. The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer. Oncogene. 2022;41(6):770–81.

Article  CAS  PubMed  Google Scholar 

Kielbik M, Szulc-Kielbik I, Klink M: E-cadherin expression in relation to clinicopathological parameters and survival of patients with epithelial ovarian cancer. Int J Mol Sci 2022, 23(22): 14383

Luo M, Li J, Yang Q, Xu S, Zhang K, Chen J, Zhang S, Zheng S, Zhou J. N4BP3 promotes breast cancer metastasis via NEDD4-mediated E-cadherin ubiquitination and degradation. Cancer Lett. 2022;550: 215926.

Article  CAS  PubMed  Google Scholar 

Wijshake T, Zou Z, Chen B, Zhong L, Xiao G, Xie Y, Doench JG, Bennett L, Levine B: Tumor-suppressor function of Beclin 1 in breast cancer cells requires E-cadherin. In: Proceedings of the National Academy of Sciences of the United States of America 2021, 118(5).

Bai X, Jiang X, Liu Y, Wang Y, Song G, Qiu H, Zhang Q. Kruppel-like factor 9 upregulates E-cadherin transcription and represses breast cancer invasion and metastasis. Am J Cancer Res. 2021;11(7):3660–73.

CAS  PubMed  PubMed Central  Google Scholar 

Karsten N, Kolben T, Mahner S, Beyer S, Meister S, Kuhn C, Schmoeckel E, Wuerstlein R, Harbeck N, Ditsch N, et al. The role of E-Cadherin expression in primary site of breast cancer. Arch Gynecol Obstet. 2022;305(4):913–20.

Article  CAS  PubMed  Google Scholar 

Wang Y, Sun Y, Shang C, Chen L, Chen H, Wang D, Zeng X. Distinct Ring1b complexes defined by DEAD-box helicases and EMT transcription factors synergistically enhance E-cadherin silencing in breast cancer. Cell Death Dis. 2021;12(2):202.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vareslija D, Ward E, Purcell SP, Cosgrove NS, Cocchiglia S, O’Halloran PJ, Charmsaz S, Bane FT, Brett FM, Farrell M, et al. Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. Oncogene. 2021;40(7):1318–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81–92.

Article  CAS  PubMed  Google Scholar 

Gao XN, Yan F, Lin J, Gao L, Lu XL, Wei SC, Shen N, Pang JX, Ning QY, Komeno Y, et al. AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia. 2015;29(8):1730–40.

Article  CAS  PubMed  Google Scholar 

Kim G, Kim JY, Lim SC, Lee KY, Kim O, Choi HS. SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development. FASEB J. 2018;32(10):5647–60.

Article  CAS  PubMed  Google Scholar 

Stolzenburg S, Beltran AS, Swift-Scanlan T, Rivenbark AG, Rashwan R, Blancafort P. Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene. 2015;34(43):5427–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Xiong W, Liu X, Xiao W, Guo Y, Tan J, Li Y. Hypomethylation at non-CpG/CpG sites in the promoter of HIF-1alpha gene combined with enhanced H3K9Ac modification contribute to maintain higher HIF-1alpha expression in breast cancer. Oncogenesis. 2019;8(4):26.

Article  PubMed  PubMed Central  Google Scholar 

Yu Z, Xiao Q, Zhao L, Ren J, Bai X, Sun M, Wu H, Liu X, Song Z, Yan Y, et al. DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis. Mol Carcinog. 2015;54(9):707–19.

Article  CAS  PubMed  Google Scholar 

Liu J, Pang Y, Wang H, Li Y, Sun X, Xu F, Ren H, Liu D. miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a. Chinese J Cell Mol Immunol. 2016;32(3):299–303.

Google Scholar 

Iwamoto T, Niikura N, Ogiya R, Yasojima H, Watanabe KI, Kanbayashi C, Tsuneizumi M, Matsui A, Fujisawa T, Iwasa T, et al. Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. Sci Rep. 2019;9(1):13343.

Article  PubMed  PubMed Central  Google Scholar 

Diao C, Guo P, Yang W, Sun Y, Liao Y, Yan Y, Zhao A, Cai X, Hao J, Hu S, et al. SPT6 recruits SND1 to co-activate human telomerase reverse transcriptase to promote colon cancer progression. Mol Oncol. 2021;15(4):1180–202.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jariwala N, Rajasekaran D, Mendoza RG, Shen XN, Siddiq A, Akiel MA, Robertson CL, Subler MA, Windle JJ, Fisher PB, et al. Oncogenic role of SND1 in development and progression of hepatocellular carcinoma. Can Res. 2017;77(12):3306–16.

Article  CAS  Google Scholar 

Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, Baldwin AS Jr, Fisher PB, Sarkar D. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem. 2012;287(17):13952–8.